ArticlePloS one2025
Variability of the lymphocyte-to-monocyte ratio in patients with chronic kidney disease on hemodialysis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive value of the Naples Prognostic Score for rapid kidney function decline in stage 3-4 CKD: a multicenter study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic kidney disease (CKD) is a global public health issue characterized by a state of persistent inflammation that leads to immune system dysregulation. The lymphocyte-to-monocyte ratio (LMR) has emerged as an inflammatory biomarker of interest for monitoring the progression of this condition.
objectiveTo determine the clinical-epidemiological, biochemical, and hematological characteristics associated with differences in the LMR in patients with chronic kidney disease undergoing hemodialysis. MATERIALS AND
methodsA retrospective cohort study was conducted by reviewing the medical records of 120 CKD patients on hemodialysis treated at a private nephrology center in Lima, Peru. Patients were divided into two groups based on the median LMR value: high LMR (< 3.06) and low LMR (≥ 3.06). Logistic regression was used to analyze risk factors associated with LMR variation, complemented by longitudinal regression analysis (up to three years follow-up).
resultsThe median age of the patients was 58 years at the time of analysis. Chronic glomerulonephritis, arterial hypertension, and type 2 diabetes mellitus (T2DM) were the most frequently reported causes of end-stage CKD. A total of 54.2% of patients had been on hemodialysis for more than seven years. Risk factors associated with decreased LMR, and thus with increased inflammation, were: older age (OR = 1.03, p < 0.001), more than three years on hemodialysis (OR = 2.17, p = 0.002), more than seven years on hemodialysis (OR = 2.38, p < 0.001), and presence of T2DM (OR = 2.2, p = 0.006). In addition, a direct positive contribution was found with hematocrit levels (Beta = 0.25, p < 0.001) and the presence of an arteriovenous fistula (Beta = 0.17, p = 0.038).
conclusionsA reduced LMR is a useful inflammatory biomarker for monitoring CKD severity. Increased age, prolonged duration of hemodialysis (more than three years), presence of T2DM, and elevated ferritin levels are associated with lower LMR values. In contrast, higher hematocrit levels and the presence of an arteriovenous fistula are directly associated with higher LMR values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.